Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | cytochrome P450, putative | 0.0105 | 1 | 1 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0058 | 0 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0105 | 1 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0105 | 1 | 1 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0105 | 1 | 1 |
Leishmania major | cytochrome p450-like protein | 0.0105 | 1 | 1 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0105 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0105 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 monooxygenase 142 Cyp142 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 139 Cyp139 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Possible cytochrome P450 126 Cyp126 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 132 Cyp132 | 0.0058 | 0 | 0.5 |
Toxoplasma gondii | cytochrome p450 superfamily protein | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Possible cytochrome P450 135B1 Cyp135B1 | 0.0058 | 0 | 0.5 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0105 | 1 | 1 |
Mycobacterium tuberculosis | Probable cytochrome P450 144 Cyp144 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 143 Cyp143 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Cytochrome P450 121 Cyp121 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 123 Cyp123 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 140 Cyp140 | 0.0058 | 0 | 0.5 |
Echinococcus multilocularis | 0.0058 | 0 | 0.5 | |
Mycobacterium tuberculosis | Probable cytochrome P450 130 Cyp130 | 0.0058 | 0 | 0.5 |
Echinococcus granulosus | cytochrome P450 2K1 | 0.0058 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0058 | 0 | 0.5 |
Brugia malayi | Cytochrome P450 family protein | 0.0105 | 1 | 1 |
Mycobacterium leprae | putative cytochrome p450 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 141 Cyp141 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Possible cytochrome P450 135A1 Cyp135A1 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 137 Cyp137 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 138 Cyp138 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 125 Cyp125 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Cytochrome P450 51 Cyp51 (CYPL1) (P450-L1A1) (sterol 14-alpha demethylase) (lanosterol 14-alpha demethylase) (P450-14DM) | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 128 Cyp128 | 0.0058 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 124 Cyp124 | 0.0058 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 5.6 uM | Compound was tested for its ability to inhibit ADP-induced human platelet aggregation | ChEMBL. | No reference |
IC50 (functional) | = 5.6 uM | Compound was tested for its ability to inhibit ADP-induced human platelet aggregation | ChEMBL. | No reference |
Relative potency (functional) | = 0.5 | Potency of the compound to inhibit ADP-induced human platelet aggregation was determined relative to compound 1(5-Methyl-3-morpholin-4-yl-6-(2-naphthalene-1-one) | ChEMBL. | No reference |
Relative potency (functional) | = 0.5 | Potency of the compound to inhibit ADP-induced human platelet aggregation was determined relative to compound 1(5-Methyl-3-morpholin-4-yl-6-(2-naphthalene-1-one) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.